Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges
Drug Repurposing for Emerging Infectious Diseases and Cancer
; : 451-478, 2023.
Artículo
en Inglés
| Scopus | ID: covidwho-20244239
ABSTRACT
Repurposed drugs such as Remdesivir, Fabipiravir and Molnupiravir became life saver drugs during the peak of the COVID-19 pandemic, attesting the efficacy of the repurposing approach. By definition, drug repurposing is the process of identification of new therapeutic use of an existing drug or drug candidate that has already passed the safety, toxicity and pharmacology tests for human use. Although drug repurposing approach involves a significant level of challenge, affordability and faster discovery pipeline outweighs the risks in the event of emergency situations like the current COVID-19 pandemic. In this chapter, we provide a brief summary of the advantages of the drug repurposing approach, followed by an overview of the drug repurposing pipeline and finally end with an update on the status of drug repurposing in developing effective anti-viral therapeutics against COVID-19. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2023.
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
Scopus
Tipo de estudio:
Estudio pronóstico
Idioma:
Inglés
Revista:
Drug Repurposing for Emerging Infectious Diseases and Cancer
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS